Diffractaic acid, a novel TrxR1 inhibitor, induces cytotoxicity, apoptosis, and antimigration in human breast cancer cells
In conclusion, these data reveal that diffractaic acid may be considered an effective therapeutic agent for breast cancer treatment.PMID:35569514 | DOI:10.1016/j.cbi.2022.109984
Source: Chemico-Biological Interactions - Category: Molecular Biology Authors: Şeyda Nur Kalın Ahmet Altay Harun Budak Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Genetics | Molecular Biology | Women